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Background: Staphylococcus aureus is a facultatively
anaerobic, Gram-positive coccus. It is a major pathogen
associated with serious community and hospital-
acquired infections. By designation methicillin resistant
Staphylococcus aureus (MRSA) is a strain of Staphylococcus
aureus that is resistant to all beta-lactams, including
penicillins, cephalosporins and carbapenems.
Vancomycin has a narrow spectrum of activity, restricted
to most Gram-positive bacteria, and is the drug
of choice for the treatment of methicillin resistant
Staphylococcus aureus. This agent, however, requires
intravenous administration, and occasionally patients
experience unacceptable side effects. Linezolid, a member
of the new oxazolidinone class of antibiotics, has
shown very good activity against methicillin resistant
Staphylococcus aureus, has excellent oral bioavailability
and is inexpensive as compared to vancomycin.
Aims and Objectives: Comparison of in vitro activities
of vancomycin and linezolid against methicillin resistant
Staphylococcus aureus.
Materials and Method: The study was conducted over
a period of 6 months. Fifty Methicillin resistant
Staphylococcus aureus isolated from the clinical isolates
of Military hospital Rawalpindi were subjected to the
determination of Minimum inhibitory concentrations of
linezolid and vancomycin using E-strips. Minimum inhibitory
concentrations 50 and minimum inhibitory concentrations
90 were calculated.
Results: All the isolated organisms were uniformly
susceptible to both the antibiotics. Vancomycin showed
higher minimum inhibitory concentrations (MICs) as
compared to linezolid MICs.
Conclusion: This study suggests that linezolid and
vancomycin have similar in vitro efﬁcacy for methicillin
resistant Staphylococcus aureus infections. Linezolid’s oral
dosing option can allow earlier discharge of hospitalized
patients and its low cost reduces health care expenses.
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Introduction: Methicillin resistant Staphylococcus aureus
(MRSA) is a strain of Staphylococcus aureus that is resistant
to all beta-lactams, including the penicillins, cephalosporins
and carbapenams. It is implicated in serious hospital and
community acquired infections.
Vancomycin is the drug of choice for the treatment of MRSA.
The rapid emergence of resistance against Vancomycin in
world necessitated the study to be done in our set up to ﬁnd
out emergence of Vancomycin intermediate and resistant
MRSA.
Objective: The objective of this study was to monitor
the current status of Vancomycin susceptibility for the
presence of vancomycin resistant or intermediate strains
of Staphylococcus aureus in our set up.
Materials and Methods: This descriptive cross sectional
study was carried out over a period of one year. Clinical
specimens sent for culture and sensitivity to our department
were inoculated on appropriate culture media and
incubated to get growth of bacteria. Staphylococcus aureus
were identiﬁed by recommended methods. Methicillin
resistance was tested by modiﬁed Kirby-Bauer disk diffusion
technique and minimum inhibitory concentrations (MIC) for
vancomycin were detected by the use of E-strips. MIC50 and
MIC90 were calculated.
Results: Most of MRSA were isolated from Pus followed
by nasobronchial lavage samples. All MRSA were sensitive
to Vancomycin but majority strains showed higher MICs
almost reaching break point. One isolate was found
to be heterogeneous GISA (Glycopepetide intermediate
Staphylococcus aureus).
Conclusion: There is emergence of reduced susceptibility
of vancomycin against MRSA. Alternatives for treatment
of MRSA should be considered and indiscriminate use of
Vancomycin should be avoided to decrease the chances
of vancomycin intermediate and vancomycin resistant
Staphylococcus aureus strains emergence.
PP-004 Comparison of in vitro efﬁcacy of linezolid,
tigecycline and chloramphenicol against
methicillin resistant Staphylococcus aureus
(MRSA) isolated from tertiary care hospital of
Pakistan
F. Kaleem1 *, J. Usman1, A. Hassan1, A. Khalid1. 1National
University of Sciences and Technology, AMC, Pakistan
Introduction: Staphylococcus aureus is a major pathogen
associated with serious community and hospital-
acquired infections. By designation methicillin resistant
Staphylococcus aureus (MRSA) is a strain of Staphylococcus
aureus that is resistant to all beta-lactams, including
penicillins, cephalosporins and carbapenems. Vancomycin
has a narrow spectrum of activity, restricted to most
Gram-positive bacteria, and is the drug of choice for
the treatment of MRSA. This agent, however, requires
intravenous administration, and occasionally patients
experience unacceptable side effects and there is rapid
emergence of resistance against this drug. Linezolid has
shown very good activity against MRSA, has excellent
oral bioavailability and is inexpensive as compared to
vancomycin. Tigecycline a new addition to tetracyclines
has also shown good results but chloramphenicol an older,
inexpensive and easy to administer drug is also found to be
highly effective against MRSA.
Aims and Objectives: Comparison of in vitro activities of
chloramphenicol, tigecycline and linezolid against MRSA.
Materials and Method: The study was conducted over a
period of 6 months. Fifty MRSA isolated from the clinical
isolates of Military hospital Rawalpindi, Pakistan were
subjected to the determination of Minimum inhibitory
concentrations (MICs) of linezolid, chloramphenicol and
tigecycline using E-strips. MIC50 and MIC90 were calculated.
Results: All the isolated organisms were highly susceptible
to these antibiotics. MRSA were 100% susceptible to
linezolid, 94% to chloramphenicol and 93% to tigecycline.
Conclusion: This study suggests that linezolid, clorampheni-
col and tigecycline have high in vitro efﬁcacy for MRSA
infections. Linezolid’s and cloramphenicol’s oral dosing
options can allow earlier discharge of hospitalized patients
and their low cost reduces health care expenses and can also
help in reducing chances of Vancomycin resistant strains.
